Increasing Treatment Options for Small Cell Lung Cancer Patients
The FDA has approved a new combination of immunotherapy and chemotherapy as an initial treatment for extensive-stage small cell...
Progress Against Cancer
The FDA has approved a new combination of immunotherapy and chemotherapy as an initial treatment for extensive-stage small cell...
The FDA approved using a combination of nivolumab and ipilimumab, two immune checkpoint inhibitors, to treat certain patients with...
The FDA has approved the immunotherapeutic isatuximab-irfc (Sarclisa) to treat certain patients with multiple myeloma. The U.S. Food and...
The FDA has expanded the use of the molecularly targeted therapeutic neratinib to include the treatment of certain patients...
Editor’s Note: On May 11, 2026, the FDA announced the voluntary withdrawal of tazemetostat from the market due to...
The FDA has approved a molecularly targeted treatment for certain patients with this form of soft tissue sarcoma. The...
The FDA approved the use of the targeted therapeutic olaparib to treat certain pancreatic cancer patients whose disease has...
The FDA approved a new treatment for adults with advanced breast cancer that has developed resistance to other targeted...
The FDA has approved a molecularly targeted therapeutic for patients with locally advanced or metastatic urothelial cancer. The U.S....
The FDA approved a molecularly targeted therapy to treat patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. The...